Clinical and genetic characteristics of facioscapulohumeral muscular dystrophy Landuzi

Close metadata

Objective. To describe clinical and genetic characteristics of patients from the Russian population with a variety of phenotypic variants of facioscapulohumeral muscular dystrophy Landuzi—Dezherina type 1 (FSHD 1). Material and methods. The material for the study were blood samples of 16 patients from 15 unrelated families residing in the territory of the Russian Federation, between the ages of 6 to 66 years, with symptoms of FSHD. Diagnosis was based on genealogical data analysis, neurological examination, electroneuromyographic study, indicators of activity of creatine phosphokinase (CPK) in the blood serum and molecular genetic analysis of the results, aimed at the analysis of macrosatellite D4Z4 repeats on chromosome 4. Results and conclusion. The study established the diagnosis of FSHD1 in 75% of patients. The correlation of the severity and phenotypic spectrum of FSHD1 with the age of onset was found. There was the significant clinical heterogeneity even among the 1st degree relatives in the same family. The correlation between macrosatellite D4Z4 repeats and clinical features of FSHD1 described previously in the literature was not observed.

Keywords:

progressive muscular dystrophy

facioscapulohumeral muscular dystrophy Landuzi—Dezherina

miodistrofiya Landuzi-Dejerine type 1

FSHD

shortening D4Z4 microsatellite repeats on chromosome 4q35

Authors:

Dadali E.L.

FGBU Mediko-geneticheskiĭ nauchnyĭ tsentr RAMN, Moskva

Sharkova I.V.

Zernov N.V.

Research Centre for Medical Genetics, Moscow, Russia

Rudenskaia G.E.

Mediko-geneticheskiĭ nauchnyĭ tsentr RAMN

Skoblov M.Yu.

Research Centre for Medical Genetics, Moscow, Russia

List of references:

Lunt PW, Harper PS. Genetic counselling in facioscapulohumeral muscular dystrophy. J Med Genet. 1991;28:655-664. PubMed:1941962. https://doi.org/10.1136/jmg.28.10.655
Padberg GW. Facioscapulohumeral muscular dystrophy: a clinician’s experience, in Facioscapulohumeral Muscular Dystrophy (FSHD): Clinical Medicine and Molecular Cell Biology., D. Cooper and M. Upadhhyaya, Editors. 2004, Garland Science/BIOS Scientific Publishers Limited: London, New York.
Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Trevisan CP. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a North-East Italian population sample. Clin Genet. 2009;75:550-555. PMID:19320656. https://doi.org/10.1111/j.1399-0004.2009.01158.x
Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009; 132(11):3175-3186. PMID:19767415. PMCID: PMC4038491. https://doi.org/10.1093/brain/awp236
Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E, Weinreich SS, Verbeek AL, van Engelen BG. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014;83(12):1056-1059. https://doi.org/10.1212/WNL.0000000000000797
Padberg GW. Facioscapulohumeral disease [Thesis]. Leiden, The Netherlands: Leiden University, 1982. http://hdl.handle.net/1887/25818~~HEAD=pobj
Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2006;34(1):1-15. https://doi.org/10.1002/mus.20522
Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van Engelen BG. What’s in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol. 2016;16(3):201-207. https://doi.org/10.1136/practneurol-2015-001353.
Wijmenga C, Frants RR, Brouwer OF, Moerer P, Weber JL, Padberg GW. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet. 1990;336(8716):651-653. https://doi.org/10.1016/0140-6736(90)92148-B
Vyakhireva YuV, Zernov NV, Marakhonov AV, Guskova AA, Skoblov MYu. Current approaches for treatment of muscular dystrophies. Medical Genetics. 2016;15(10):3-16. (In Russ.)
Zernov NV, Marakhonov AV, Vyakhireva YuV, Guskova AA, Dadali EL, Skoblov MYu. Glinical-genetic characteristics and diagnostic features of the fascioscapulohumeral muscular dystrophy landouzy-dejerine.Russian Journal of Genetics. 53. (In Russ.)
Lunt PW, Compston DAS, Harper PS. Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. J Med Genet. 1989;26:755-760. PubMed: 2614794. PMCID: PMC1015755. https://doi.org/10.1136/jmg.26.12.755
Zatz M, Marie SK, Passos-Bueno MR, Vainzof M, Campiotto S, Cerqueira A, Wijmenga C, Padberg G, Frants R. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet. 1995;56(1):99-105. PMID:7825608. PMCID:PMC1801310
Bakker E, Wijmenga C, Vossen RH, Padberg GW, Hewitt J, van der Wielen M, Rasmussen K, Frants RR. The FSHD-linked locus D4F104S1 (p13E-11) on 4q35 has a homologue on 10qter. Muscle Nerve Suppl. 1995;2:39-44. PMID:23573585. https://doi.org/10.1002/mus.880181309
Papa S, Guerrieri F, Zanotti F, Capozza G, Fiermonte M, Cocco T, Altendorf K, Deckers-Hebersteit G. F0 and F1 subunits involved in the gate and coupling function of mitochondrial H+ ATP synthase. Ann N Y Acad Sci. 1992;671:345-58. PMID:1288331. https://doi.org/10.1111/j.1749-6632.1992.tb43808.x
Gaillard MC, Roche S, Dion C, Tasmadjian A, Bouget G, Salort-Campana E, Vovan C, Chaix C, Broucqsault N, Morere J, et al. Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers. Neurology. 2014;83(8):733-742. https://doi.org/10.1212/WNL.0000000000000708
Tonini MM, Pavanello RC, Gurgel-Giannetti J, Lemmers RJ, van der Maarel SM, Frants RR, Zatz M. Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more severe phenotype. J Med Genet. 2004;41(2):17. https://doi.org/10.1136/jmg.2003.010637
Ebe Pastorello, Michelangelo Cao, Carlo P. Trevisan et al. Atypical onset in a series of 122 cases with Facio Scapulo Humeral Muscular Dystrophy. Clinical Neurology and Neurosurgery. 2012;114:3:230-234. https://doi.org/10.1016/j.clineuro.2011.10.022
Tai-Heng Chen, Yu-Hung Lai, Pei-Lun Lee, Jong-Hau Hsu, Kanako Goto, Yukiko K. Hayashi, Ichizo Nishino, Chin-Wen Lin, Hsiang-Hung Shih, Chao-Ching Huang, Wen-Chen Liang, Wen-Fu Wang, Yuh-Jyh Jong. Infantile facioscapulohumeral muscular dystrophy revisited: Expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord. 2013;23(4):298-305. https://doi.org/10.1016/j.nmd.2013.01.005
Brouwer OF, Padberg GW, Wijmenga C, Frants RR. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol. 1994;51(4):387-394. https://doi.org/10.1001/archneur.1994.00540160085011
Dorobek M, van der Maarel SM, Lemmers RJ, Ryniewicz B, Kabzinska D, Frants RR, Gawel M, Walecki J, Hausmanowa-Petrusewicz I. Early-onset facioscapulohumeral muscular dystrophy type 1 with some atypical features. J Child Neurol. 2015;30(5):580-587. https://doi.org/10.1177/0883073814528281
Klinge L, Eagle M, Haggerty ID, Roberts CE, Straub V, Bushby KM. Severe phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2006;16(9-10):553-558. https://doi.org/10.1016/j.nmd.2006.06.008
Richard JLF, Lemmers P, Daniel G, Miller MD, van der Maarel SM. Facioscapulohumeral Muscular Dystrophy. 2014.
Upadhyaya M, Cooper DN (2004) Facioscapulohumeral muscular dystrophy: clinical medicine and molecular cell biology. Garland Science/BIOS Scientific, Abingdon Google Scholar. https://doi.org/10.3109/9780203997352.086
Giulia Ricci, Isabella Scionti, Francesco Sera, Monica Govi, Roberto D’Amico, Ilaria Frambolli, Fabiano Mele, Massimiliano Filosto, Liliana Vercelli, Lucia Ruggiero et al. Large scale genotype — phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain. 2013;136(11):3408-3417. https://doi.org/10.1093/brain/awt226
Trevisan CP, Pastorello E, Tomelleri G, Vercelli L, Bruno C, Scapolan S, Siciliano G, Comacchio F. Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol. 2008;15(12):1353-1358. https://doi.org/10.1111/j.1468-1331.2008.02314.x
Miura K, Kumagai T, Matsumoto A, lriyama E, Watanabe K, Goto K, Arahata K. Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular dystrophy with mental retardation and epilepsy. Neuropediatrics. 1998;29(5):239-241. https://doi.org/10.1055/s-2007-973568
Tawil R. Facioscapulohumeral muscular dystrophy. Neurotherapeutics. 2008;5(4):601-606. PMID:19019312. PMCID:PMC2628543. https://doi.org/10.1016/j.nurt.2008.07.005
Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M, Harper PS, Upadhyaya M. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generation effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Molec Genet. 1995;4:951-958. Note: Erratum: Hum Molec Genet. 1995;4:1243-1244. PubMed:7633457.
Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, King W, Weiffenbach B, Figlewicz D. Evidence for anticipation and association of deletion size with severity in acioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol. 1996;39(6):744-748. PMID:8651646. https://doi.org/10.1002/ana.410390610
Tawil R, Storvick D, Feasby TE, Weiffenbach B, Griggs RC. Extreme variability of expression in monozygotic twins with FSH muscular dystrophy. Neurology. 1993;43(2):345-348. PMID: 8094896. https://doi.org/10.1212/wnl.43.2.345

Close metadata